Baxter International | BAX - Current Liabilities


Baxter International reported $3.59B in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Abbott USD 18.38B 1.88B Mar/2026
AngioDynamics USD 71.96M 3.68M Sep/2025
Artivion USD 106.93M 14.23M Jun/2026
AtriCure USD 81.92M 8.72M Jun/2026
Baxter International USD 3.59B 102M Jun/2026
Becton, Dickinson and Co. USD 9.4B 897M Jun/2026
Boston Scientific USD 6.43B 1.86B Jun/2026
Cooper Companies USD 1.8B 209M Mar/2026
Dexcom USD 2.36B 133.9M Jun/2026
Edwards Lifesciences USD 1.51B 98.9M Jun/2026
Fresenius EUR 9.07B 468M Jun/2026
Globus Medical USD 479.35M 3.12M Jun/2026
Halozyme Therapeutics USD 344.44M 18.77M Jun/2026
ICU Medical USD 498.36M 19.54M Jun/2026
Inogen USD 64.94M 2.12M Sep/2025
Insulet USD 744.2M 56.7M Jun/2026
Integra LifeSciences USD 330.88M 15.96M Jun/2026
Intuitive Surgical USD 2.58B 65.1M Jun/2026
J&J USD 54.9B 2.82B Jun/2026
Laboratory Of America USD 2.12B 516.4M Jun/2026
Medtronic USD 9.5B 440M Dec/2025
Merit Medical Systems USD 264.93M 48.06M Jun/2026
Quest Diagnostics USD 1.79B 389M Jun/2026
Smith & Nephew USD 2.05B 510M Jun/2026
Stryker USD 6.68B 369M Jun/2026
Tandem Diabetes Care USD 253M 5.05M Jun/2026
Teleflex USD 720.38M 7.67M Jun/2026
Terumo JPY 413.28B 127.46B Jun/2026
Zimmer Biomet Holdings USD 3.01B 149.2M Jun/2026